Table 1.
Clinical Characteristics of Patients.
| Study | n | Age, median (range), year | Male, % | Disease type | Disease status at ASCT | Follow-up, median (range), months |
|---|---|---|---|---|---|---|
| Lachance et al. 30 | ||||||
| BeEAM | 131 | 56 (47–65) | 64 | HD 14%, NHL 86% | CR 76%, PR/SD/PD 24% | 48 |
| BEAM/BEAC | 96 | 51 (39–63) | 55 | HD 25%, NHL 75% | CR 64%, PR/SD/PD 36% | 60 |
| Hueso et al. 26 | ||||||
| BeEAM | 60 | 59 (36–70) | 78 | MCL | CR 82%, PR/SD/PD 18% | 37 (1–49) |
| BEAM | 108 | 58 (31–69) | 84 | MCL | CR 60%, PR/SD/PD 40% | 36 (1–154) |
| Glover et al. 28 | ||||||
| BeEAM | 49 | 59 (23–71) | 73 | HD 20%, NHL 80% | PR/SD/PD 100% | 12.8 |
| BEAM | 98 | 59 (23–69) | 62 | HD 20%, NHL 80% | PR/SD/PD 100% | 41.2 |
| AlJohani et al. 29 | ||||||
| BeEAM | 17 | 31 (21–60) | 53 | HD 76%, NHL 24% | CR 6%, PR/SD 94% | 14.62 (1.61–19.45) |
| BEAM | 54 | 23.69 (15.05–59.06) | 52 | HD 72%, NHL 28% | CR 13%, PR/SD 87% | 29.88 (0.76–127.11) |
| Lucijanic et al. 25 | ||||||
| BeEAM | 17 | 50 (39–56) | 47 | HD 13%, NHL 87% | NA | NA |
| BEAM | 43 | 52 (38.5–59) | 56 | HD 14%, NHL 86% | NA | NA |
| Frankiewicz et al. 27 | ||||||
| BeEAM | 63 | 45 (21.5–72.8) | 59 | HD 40%, NHL 60% | CR 53%, PR/SD/PD 47% | 9 |
| BEAM | 174 | 46.5 (19.5–69.4) | 60 | HD 49%, NHL 51% | CR 59%, PR/SD/PD 41% | 29 |
| Hahn et al. 23 | ||||||
| BeEAM | 41 | 55 (43–67) | 76 | HD 17%, NHL 83% | NA | NA |
| BEAM | 86 | 51 (38–64) | 58 | HD 33%, NHL 67% | NA | NA |
| Saleh et al. 31 | ||||||
| BeEAM | 34 | 49 (21–68) | 62 | HD 26%, NHL 74% | CR 62%, PR 38% | 18 (2–28) |
| BEAM | 68 | 52.5 (21–71) | 62 | HD 26%, NHL 74% | CR 60%, PR 40% | 45 (2–126) |
| Tsang et al. 32 | ||||||
| BeEAM | 26 | 29 (16–66) | 54 | HD | CR/PR 73%, SD/PD 27% | 43.2 (10–96) |
| BEAM | 52 | 32 (17–62) | 60 | HD | CR/PR 73%, SD/PD 27% | 46.8 (13.2–120) |
| Garciaz et al. 24 | ||||||
| BeEAM | 29 | 58 (19–68) | 62 | DLBCL 62%, MCL 38% | CR 100% | NA |
| BEAM | 58 | 54 (25–65) | 69 | DLBCL 69%, MCL 31% | CR 100% | NA |
ASCT: autologous stem cell transplantation; BEAC: carmustine, etoposide, cytarabine, cyclophosphamide; BEAM: carmustine, etoposide, cytarabine, melphalan; BeEAM: bendamustine, etoposide, cytarabine, melphalan; DLBCL: diffuse large B-cell lymphoma; MCL: mantle cell lymphoma; NHL: non-Hodgkin’s lymphoma.